Organogenesis Inc. is a leading regenerative medicine company with the unique skill set to take complex, living therapies from research and development, through manufacturing, to successful commercialization to reach patients today. As a pioneer in the field of regenerative medicine, Organogenesis received the first FDA approval of a living, allogeneic, cell-based product Apligraf®, approved for the treatment of venous leg ulcers.